OncoMatch/Clinical Trials/NCT06649812
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Is NCT06649812 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments for high grade b-cell lymphoma with myc and bcl6 rearrangements.
Treatment: Ibrutinib · Lenalidomide · Obinutuzumab · Prednisone · Venetoclax — This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD10 loss
Cohort 1: CD10-negative DLBCL
Required: MYC rearrangement
CD10-negative HGBCL with MYC and BCL6 (without BCL2) translocations (HGBCL-DH-BCL6)
Required: BCL6 rearrangement
CD10-negative HGBCL with MYC and BCL6 (without BCL2) translocations (HGBCL-DH-BCL6)
Required: MYC rearrangement
Cohort 2: CD10-positive or negative HGBCL with MYC and BCL2 rearrangements (with or without BCL6 rearrangement) (HGBCL-DH-BCL2)
Required: BCL2 rearrangement
Cohort 2: CD10-positive or negative HGBCL with MYC and BCL2 rearrangements (with or without BCL6 rearrangement) (HGBCL-DH-BCL2)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anthracycline and anti-CD20 antibody-containing regimen
relapsed and/or refractory disease after at least 1 prior anthracycline and anti-CD20 antibody-containing regimen
Cannot have received: cytotoxic chemotherapy
Exception: no more than 3 prior lines of cytotoxic chemotherapy, excluding targeted therapy, anti-cancer antibodies, antibody-drug conjugates, bi-specific antibodies, and radio- or toxin-immunoconjugates
More than 3 prior lines of cytotoxic chemotherapy, excluding targeted therapy, anti-cancer antibodies, antibody-drug conjugates, bi-specific antibodies, and radio- or toxin-immunoconjugates
Cannot have received: venetoclax, ibrutinib, lenalidomide, or other BCL2 inhibitor, BTK inhibitor, or IMiD (venetoclax, ibrutinib, lenalidomide)
Exception: no more than one of the following study agents: venetoclax (or another BCL2 inhibitor), ibrutinib (or another BTK inhibitor), or lenalidomide (or another IMiD)
Previous treatment with more than one of the following study agents: venetoclax (or another BCL2 inhibitor), ibrutinib (or another BTK inhibitor), or lenalidomide (or another immunomodulatory imide drug [IMiD])
Lab requirements
Blood counts
ANC ≥ 1,000/mcL without G-CSF support; Hemoglobin ≥ 8 g/dL; Platelets ≥ 75,000/mcL without platelet transfusion support
Kidney function
Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min/1.73 m^2
Liver function
Total bilirubin ≤ 1.5 x institutional ULN (or ≤ 3.0 x institutional ULN for patients with documented Gilberts syndrome); AST/ALT ≤ 3.0 x institutional ULN
Cardiac function
NYHA class 2B or better
ANC ≥ 1,000/mcL without G-CSF support; Hemoglobin ≥ 8 g/dL; Platelets ≥ 75,000/mcL without platelet transfusion support; Total bilirubin ≤ 1.5 x institutional ULN (or ≤ 3.0 x institutional ULN for patients with documented Gilberts syndrome); AST/ALT ≤ 3.0 x institutional ULN; Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min/1.73 m^2; NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner University Medical Center - Tucson · Tucson, Arizona
- University of Arizona Cancer Center-North Campus · Tucson, Arizona
- Cedars-Sinai Medical Center · Los Angeles, California
- Smilow Cancer Hospital-Derby Care Center · Derby, Connecticut
- Smilow Cancer Hospital Care Center - Guilford · Guilford, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06649812 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy, venetoclax, ibrutinib, lenalidomide, or other BCL2 inhibitor, BTK inhibitor, or IMiD disqualifies patients from enrollment.
Does this trial require CD10?
Yes, CD10 loss is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC rearrangement is a required biomarker for enrollment.
Does this trial require BCL6?
Yes, BCL6 rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify